Immune Response Protein Production Vaccine Virus 
Drug Discovery World
FEBRUARY 19, 2024
Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).
Drug Discovery World
AUGUST 1, 2023
As per a definition provided by AstraZeneca: “Once inside, ASOs bind with high specificity to target mRNA or pre-mRNA, inducing its degradation – effectively silencing it – to prevent its translation into a detrimental protein product.
Drug Discovery World
NOVEMBER 8, 2023
The presentations include: Mark Cragg, PhD, Professor of Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, on: ‘Modulating antibody effector functions in the tumour microenvironment’.
Expert insights. Personalized for you.
130 
Let's personalize your content